Understanding COVID-19 in transplant recipients
Prevalence and Outcome of SARS-CoV-2 Infection in Solid Organ and Hematopoietic Cell Transplant Recipients: The COVITRA Study
This study is trying to learn how COVID-19 affects transplant patients by looking at their immune responses and the factors that might help or hurt them during infection.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Universitaire Ziekenhuizen KU Leuven Academic / other |
| Locations | 1 site (Leuven, Vlaams Brabant) |
| Trial ID | NCT04579471 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather data from over 3000 transplant patients to identify risk and protective factors associated with SARS-CoV-2 infection and the severity of COVID-19. It will assess the proportion of patients who develop antibodies post-infection and evaluate the duration of these antibodies, as well as their potential protective effects against reinfection. The study will provide valuable insights into the immune response of transplant recipients to COVID-19.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals who have undergone solid organ or hematopoietic cell transplantation and are able to provide informed consent.
Not a fit: Patients under 18 years of age will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of COVID-19 in transplant patients and inform better management strategies for this vulnerable population.
How similar studies have performed: Other studies have shown success in understanding COVID-19 impacts on immunocompromised populations, making this approach both relevant and necessary.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * all patients who underwent solid organ or hematopoietic cell transplantation at UZ Leuven and who give informed consent Exclusion Criteria: * age under 18 years
Where this trial is running
Leuven, Vlaams Brabant
- UZ Leuven — Leuven, Vlaams Brabant, Belgium (Recruiting)
Study contacts
- Principal investigator: Jef Verbeek, MD, PhD — UZ Leuven
- Study coordinator: Jef Verbeek, MD, PhD
- Email: jef.verbeek@uzleuven.be
- Phone: + 32 16 34 42 25
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.